J. Goldman & Co LP Sells 9,733 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

J. Goldman & Co LP cut its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 15.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,503 shares of the company's stock after selling 9,733 shares during the period. J. Goldman & Co LP owned 0.07% of SpringWorks Therapeutics worth $1,933,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Los Angeles Capital Management LLC boosted its holdings in SpringWorks Therapeutics by 30.8% in the fourth quarter. Los Angeles Capital Management LLC now owns 61,760 shares of the company's stock valued at $2,231,000 after acquiring an additional 14,548 shares during the last quarter. Schroder Investment Management Group lifted its stake in SpringWorks Therapeutics by 93.6% in the fourth quarter. Schroder Investment Management Group now owns 168,209 shares of the company's stock valued at $6,113,000 after buying an additional 81,314 shares during the period. Vanguard Group Inc. lifted its stake in SpringWorks Therapeutics by 6.6% in the fourth quarter. Vanguard Group Inc. now owns 7,158,871 shares of the company's stock valued at $258,650,000 after buying an additional 445,593 shares during the period. BIT Capital GmbH lifted its stake in SpringWorks Therapeutics by 18.7% in the fourth quarter. BIT Capital GmbH now owns 53,539 shares of the company's stock valued at $1,934,000 after buying an additional 8,429 shares during the period. Finally, Platinum Investment Management Ltd. acquired a new position in SpringWorks Therapeutics in the fourth quarter valued at approximately $1,694,000.

Analysts Set New Price Targets

Several equities analysts have issued reports on SWTX shares. Evercore ISI lowered SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 28th. Barclays reissued an "equal weight" rating and issued a $47.00 price target (down from $63.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Guggenheim reissued a "neutral" rating and issued a $47.00 price target on shares of SpringWorks Therapeutics in a research note on Monday, May 12th. TD Cowen reissued a "hold" rating and issued a $47.00 price target (down from $66.00) on shares of SpringWorks Therapeutics in a research note on Tuesday, April 29th. Finally, Wedbush reissued a "neutral" rating and issued a $47.00 price target (down from $81.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Seven analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, SpringWorks Therapeutics has an average rating of "Hold" and an average price target of $52.57.

SpringWorks Therapeutics Stock Up 0.1%

NASDAQ SWTX traded up $0.03 on Friday, reaching $46.11. The company had a trading volume of 7,025,072 shares, compared to its average volume of 2,105,694. The stock has a market capitalization of $3.46 billion, a P/E ratio of -13.25 and a beta of 0.77. The company's fifty day moving average is $43.95 and its 200 day moving average is $42.24. SpringWorks Therapeutics, Inc. has a 52-week low of $28.21 and a 52-week high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.30). The company had revenue of $49.09 million during the quarter, compared to analysts' expectations of $64.19 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. On average, research analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current year.

Insider Activity at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, insider Bhavesh Ashar sold 1,016 shares of the company's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $61.19, for a total value of $62,169.04. Following the completion of the transaction, the insider now owns 62,053 shares in the company, valued at $3,797,023.07. This represents a 1.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Saqib Islam sold 29,328 shares of the company's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $60.30, for a total value of $1,768,478.40. Following the completion of the transaction, the chief executive officer now owns 1,034,625 shares of the company's stock, valued at $62,387,887.50. This trade represents a 2.76% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 146,944 shares of company stock valued at $8,439,479. 7.83% of the stock is owned by insiders.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.